2022 Á¦ 23ȸ ´ëÇÑÅõ¼®Çùȸ ½ÉÆ÷Áö¾ö : 2022-09-25±³À°ÀÏÀÚ : 2022-09-25
±³À°Àå¼Ò : ´õÄÉÀÌÈ£ÅÚ ¼¿ï, ´õÄÉÀÌÈ£ÅÚ ÄÁº¥¼Ç¼¾ÅÍ ±×·£µåº¼·ë A room+B room
±³À°ÁÖÁ¦ :
2022 Á¦ 23ȸ ´ëÇÑÅõ¼®Çùȸ ½ÉÆ÷Áö¾öÁÖÃÖ±â°ü : ´ëÇѽÅÀåÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ´ëÇÑÅõ¼®Çùȸ
´ã´çÀÚ : ±ÇÇöÁ¤
¿¬¶ôó : 02-521-0458
À̸ÞÀÏ :
office@e-kda.org ±³À°Á¾·ù : ³»°ú
Âü¼®¿¹»óÀοø : 700¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 6 ½Ã°£ 15ºÐ
¼¼ºÎ¼ö°·á : 60,000¿ø
ºñ°í ¡á»çÀüµî·Ï (ÀÇ»ç: 5¸¸¿ø / °£È£»ç: 4¸¸¿ø) ¡áÇöÀåµî·Ï (ÀÇ»ç:6¸¸¿ø / °£È£»ç 5¸¸¿ø)
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 09-25 ±×·£µåº¼·ë 09:00~09:25 Prevention strategies for minimizing COVID-19 infection in dialysis facilities À¯°æµ·(¿ï»êÀÇ´ë)
±³À°½Ã°£ 09-25 ±×·£µåº¼·ë 09:25~09:50 Outcomes in dialysis patients infected with COVID-19 patients ±èµµÇü(ÇѸ²ÀÇ´ë)
±³À°½Ã°£ 09-25 ±×·£µåº¼·ë 09:50~10:15 Infection control in dialysis facility ÀÌÇѱÔ(ÀÌÇѱԳ»°ú)
Åä·Ð 09-25 ±×·£µåº¼·ë 10:15~10:20 Discussion ÀÌÇѱÔ(ÀÌÇѱԳ»°ú)
ÈÞ½Ä 09-25 ±×·£µåº¼·ë 10:20~10:40 Coffee Break ()
±³À°½Ã°£ 09-25 ±×·£µåº¼·ë 10:40~11:05 Protein energy wasting syndrome ±èÁØö(Â÷ÀÇ´ë)
±³À°½Ã°£ 09-25 ±×·£µåº¼·ë 11:05~11:30 Tissue calcification and PAD(Peripheral arterial disease) ±è±âÇ¥(ÀÎÇÏÀÇ´ë)
±³À°½Ã°£ 09-25 ±×·£µåº¼·ë 11:30~11:55 Sudden death and cardiac arrhythmia in dialysis patients Á¶ÁØȯ(Áß¾ÓÀÇ´ë)
Åä·Ð 09-25 ±×·£µåº¼·ë 11:55~12:00 Discussion Á¶ÁØȯ(Áß¾ÓÀÇ´ë)
½Ä»ç 09-25 ±×·£µåº¼·ë 12:00~13:00 Lunch ()
±³À°½Ã°£ 09-25 ±×·£µåº¼·ë 13:00~13:40 High volume HDF(Hemodiafiltration) prescription ±èµµÇü(ÇѸ²ÀÇ´ë)
±³À°½Ã°£ 09-25 ±×·£µåº¼·ë 13:40~14:05 Hyperkalemia management ±â¿¬°æ(ÇѸ²ÀÇ´ë)
±³À°½Ã°£ 09-25 ±×·£µåº¼·ë 14:05~14:30 Hyperphosphatemia management ±èÁöÀº(°í·ÁÀÇ´ë)
±³À°½Ã°£ 09-25 ±×·£µåº¼·ë 14:30~14:55 Anemia management ȲÁøÈ£(Áß¾ÓÀÇ´ë)
Åä·Ð 09-25 ±×·£µåº¼·ë 14:55~15:05 Discussion ȲÁøÈ£(Áß¾ÓÀÇ´ë)
ÈÞ½Ä 09-25 ±×·£µåº¼·ë 15:05~15:25 Coffee Break ()
±³À°½Ã°£ 09-25 ±×·£µåº¼·ë 15:25~15:45 Uric acid lowering agent ¿ÀÅ·Å(Àü³²ÀÇ´ë)
±³À°½Ã°£ 09-25 ±×·£µåº¼·ë 15:45~16:05 Indoxyl sulfate chelating agent ¾ÈÁ¤³²(¼¿ïÀÇ´ë)
±³À°½Ã°£ 09-25 ±×·£µåº¼·ë 16:05~16:25 SGLT2(sodium glucose cotransporter 2) inhibitor ÁÖ¿µ¼ö(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 09-25 ±×·£µåº¼·ë 16:25~16:45 Non-steroidal mineralocorticoid receptor antagonists ¾ÈÁ¤³²(¼¿ïÀÇ´ë)
Åä·Ð 09-25 ±×·£µåº¼·ë 16:45~16:55 Discussion ¾ÈÁ¤³²(¼¿ïÀÇ´ë)